Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Alimentary Pharmacology & Therapeutics|November 22, 2017
Exposure-response relationship of certolizumab pegol induction and maintenance therapy in patients with Crohn's diseaseN Vande Casteele, B G Feagan, S Vermeire, et al.
Alimentary Pharmacology & Therapeutics|October 4, 2014
Prior response to infliximab and early serum drug concentrations predict effects of adalimumab in ulcerative colitisF Baert, N Vande Casteele, S Tops, et al.
Tissue Antigens|January 23, 1999
Characterization of a new HLA-B39 allele, B*3913, in a Brazilian CaucasianR Maertens, I De Canck, M E Moraes, et al.
Alimentary Pharmacology & Therapeutics|August 30, 2012
Detection of infliximab levels and anti-infliximab antibodies: a comparison of three different assaysN Vande Casteele, D J Buurman, M G G Sturkenboom, et al.
Alimentary Pharmacology & Therapeutics|September 15, 2015
Review article: pharmacological aspects of anti-TNF biosimilars in inflammatory bowel diseasesK Papamichael, T Van Stappen, V Jairath, et al.
Alimentary Pharmacology & Therapeutics|March 21, 2017
The effects of pregnancy on the pharmacokinetics of infliximab and adalimumab in inflammatory bowel diseaseC H Seow, Y Leung, N Vande Casteele, et al.
Alimentary Pharmacology & Therapeutics|April 18, 2018
High body mass index is associated with increased risk of treatment failure and surgery in biologic-treated patients with ulcerative colitisS Kurnool, N H Nguyen, J Proudfoot, et al.
Alimentary Pharmacology & Therapeutics|April 27, 2018
Systematic review with meta-analysis: endoscopic and histologic placebo rates in induction and maintenance trials of ulcerative colitisC Ma, L Guizzetti, R Panaccione, et al.
Alimentary Pharmacology & Therapeutics|January 12, 2017
Review article: dose optimisation of infliximab for acute severe ulcerative colitisP Hindryckx, G Novak, N Vande Casteele, et al.
Alimentary Pharmacology & Therapeutics|October 14, 2017
Review article: consensus statements on therapeutic drug monitoring of anti-tumour necrosis factor therapy in inflammatory bowel diseasesN Mitrev, N Vande Casteele, C H Seow, et al.
Pageof 1